Table 2.
Microbiological outcomes and side effects for patients, by province
| Hanoi province | Thanh Hoa province | Total | |
|---|---|---|---|
| Total | n = 494 | n = 168 | n = 662 |
| Treatment duration [median (IQR)] | |||
| Start to completion (months) | 19.0 (9.8–20.0) | 20.0 (9.7–21.3) | 19.0 (9.7–20.0) |
| Inpatient regimen (days) | 25 (16–34) | 33 (19–42) | 28 (16–37) |
| Smear conversion after 2 months | n = 454 | n = 132 | n = 586 |
| Yes | 418 (92.1%) | 85 (64.4%) | 503 (85.8%) |
| No | 36 (7.9%) | 47 (35.6%) | 83 (14.2%) |
| Not reported | 40 | 36 | 76 |
| Smear conversion after 4 months | n = 421 | n = 116 | n = 537 |
| Yes | 409 (97.1%) | 110 (94.8%) | 519 (96.6%) |
| No | 12 (2.9%) | 6 (5.2%) | 18 (3.4%) |
| Not reported | 73 | 52 | 125 |
| Culture conversion after 2 months | n = 448 | n = 105 | n = 553 |
| Yes | 405 (90.4%) | 10 (9.5%) | 415 (75.0%) |
| No | 43 (9.6%) | 95 (90.5%) | 138 (25.0%) |
| Not reported | 46 | 63 | 109 |
| Culture conversion after 4 months | n = 420 | n = 108 | n = 528 |
| Yes | 402 (95.7%) | 86 (79.6%) | 488 (92.4%) |
| No | 18 (4.3%) | 22 (20.4%) | 40 (7.6%) |
| Not reported | 74 | 60 | 134 |
| Side effects during treatment | |||
| At least one inpatient side effect reported | n = 308 | n = 144 | n = 452 |
| Yes | 23 (7.5%) | 16 (11.1%) | 39 (8.6%) |
| No | 285 (92.5%) | 128 (88.9%) | 413 (91.4%) |
| Not reported | 186 | 24 | 210 |
| At least one outpatient side effect reported | n = 447 | n = 125 | n = 572 |
| Yes | 75 (16.8%) | 32 (25.6%) | 107 (18.7%) |
| No | 372 (83.2%) | 93 (74.4%) | 465 (81.3%) |
| Not reported | 47 | 43 | 90 |
| Outpatient side effects reporteda | n = 195 | n = 52 | n = 247 |
| Blood disorder | 6 (3.1%) | 0 (0%) | 6 (2.4%) |
| Bowel pain | 3 (1.5%) | 2 (3.8%) | 5 (2.0%) |
| Hearing loss | 9 (4.6%) | 3 (5.8%) | 12 (4.9%) |
| Hepatotoxicity | 35 (17.9%) | 0 (0%) | 35 (14.2%) |
| High blood sugar | 10 (5.1%) | 0 (0%) | 10 (4.0%) |
| High uric acid | 42 (21.5%) | 0 (0%) | 42 (17.0%) |
| Hypokalemia | 15 (7.7%) | 0 (0%) | 15 (6.1%) |
| Joint pain | 19 (9.7%) | 16 (30.8%) | 35 (14.2%) |
| Loss of appetite | 11 (5.6%) | 0 (0%) | 11 (4.5%) |
| Nephrotoxicity | 17 (8.7%) | 0 (0%) | 17 (6.9%) |
| Neurotoxicity | 7 (3.6%) | 1 (1.9%) | 8 (3.2%) |
| Nausea | 0 (0%) | 23 (44.2%) | 23 (9.3%) |
| Vision loss | 7 (3.6%) | 2 (3.8%) | 9 (3.6%) |
| Vertigo | 14 (7.2%) | 5 (9.6%) | 19 (7.7%) |
| Not reported | 299 | 116 | 415 |
Bolded numbers indicate the number of individuals for whom data were available (percentages exclude those for whom data were not reported)
aPatients could report more than one side effect